KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for West Pharmaceutical Services (WST) over the last 15 years, with Q3 2025 value amounting to $8.4 million.

  • West Pharmaceutical Services' Share-based Compensation rose 6470.59% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 3544.3%. This contributed to the annual value of $18.7 million for FY2024, which is 1974.25% down from last year.
  • According to the latest figures from Q3 2025, West Pharmaceutical Services' Share-based Compensation is $8.4 million, which was up 6470.59% from $7.4 million recorded in Q2 2025.
  • Over the past 5 years, West Pharmaceutical Services' Share-based Compensation peaked at $11.3 million during Q3 2021, and registered a low of $1.3 million during Q1 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $5.9 million (2021), whereas its average is $6.3 million.
  • As far as peak fluctuations go, West Pharmaceutical Services' Share-based Compensation crashed by 7910.45% in 2023, and later soared by 20714.29% in 2024.
  • Quarter analysis of 5 years shows West Pharmaceutical Services' Share-based Compensation stood at $10.0 million in 2021, then crashed by 33.0% to $6.7 million in 2022, then plummeted by 79.1% to $1.4 million in 2023, then surged by 207.14% to $4.3 million in 2024, then skyrocketed by 95.35% to $8.4 million in 2025.
  • Its last three reported values are $8.4 million in Q3 2025, $7.4 million for Q2 2025, and $1.3 million during Q1 2025.